Axial Spondyloarthritis Drugs Market
Axial Spondyloarthritis Drugs Market Size, Share and Trends Analysis Report, By Type (Certolizumab Pegol, Etanercept Biosimilar, Ixekizumab, Secukinumab, and Others), By Application (Clinic, Hospital, and Home Care), Forecast Period (2026-2035)
Industry Overview
Axial spondyloarthritis drugs market was valued at $4.8 billion in 2025 and is projected to reach $8.5 billion by 2035, growing at a CAGR of 6.0% during the forecast period 2026-2035. The increasing prevalence of autoimmune and inflammatory conditions has contributed to the expansion of the global axial spondyloarthritis drugs market. Enhanced awareness among healthcare providers and patients regarding early detection and management has created greater demand for effective therapies. Among the treatments gaining prominence, biologic agents such as TNF inhibitors and interleukin-targeted drugs have shown significant clinical benefits. Advances in research and ongoing clinical trials continue to introduce novel therapeutic options, broadening the range of available interventions. Government support and favorable reimbursement frameworks in key regions have further facilitated market adoption.
Market Dynamics
Rising Adoption of Biologic Therapies
The axial spondyloarthritis drugs market is witnessing a notable shift toward biologic therapies, particularly TNF inhibitors and interleukin-targeted treatments. These agents are increasingly preferred due to their ability to control inflammation, slow disease progression, and improve patient quality of life. Growing clinical evidence supporting their efficacy has strengthened physician confidence and patient acceptance. Pharmaceutical companies are also expanding their biologic portfolios to address unmet treatment needs. The availability of biosimilars is enhancing affordability and accessibility, further driving adoption.
Focus on Early Diagnosis and Personalized Treatment
Early diagnosis and tailored therapeutic approaches are emerging as key drivers in the axial spondyloarthritis drugs market. Advancements in diagnostic techniques and increased awareness among healthcare providers are facilitating timely intervention. Personalized treatment regimens based on disease severity, patient comorbidities, and response to therapy are gaining prominence. Research initiatives aimed at identifying novel biomarkers and predictive indicators support more effective management strategies. Furthermore, healthcare policies and reimbursement frameworks that emphasize precision medicine are encouraging adoption.
Market Segmentation
- Based on the type, the market is segmented into certolizumab pegol, etanercept biosimilar, ixekizumab, secukinumab and others.
- Based on the application, the market is segmented into clinic, hospital and homecare.
Certolizumab Pegol Segment to Lead the Market with the Largest Share
The global axial spondyloarthritis drugs market is expanding as Certolizumab Pegol gains wider clinical adoption for the management of inflammatory conditions. Its proven efficacy in reducing disease activity and slowing disease progression has strengthened physician confidence in prescribing this therapy. Growing awareness among patients and healthcare providers about targeted biologic treatments has further accelerated its uptake. Investment in research and ongoing clinical trials continues to enhance treatment protocols and improve patient outcomes. Hospitals and specialized clinics are increasingly incorporating Certolizumab Pegol into treatment regimens, reinforcing its role in standard care. Additionally, improvements in healthcare infrastructure and supportive reimbursement policies in key regions are facilitating broader access to this therapy.
Hospital: A Key Segment in Market Growth
The global axial spondyloarthritis drugs market is witnessing substantial growth due to increasing demand from hospital settings. Hospitals provide the necessary infrastructure and specialist care required for administering advanced biologic therapies, which supports higher adoption rates. The presence of trained rheumatologists and monitoring facilities ensures effective disease management and enhances treatment outcomes. Growing patient inflow and the emphasis on comprehensive care within hospitals have further contributed to market expansion. Strategic initiatives by healthcare institutions to incorporate new therapies and optimize treatment protocols are reinforcing hospital-driven growth. In addition, government support and reimbursement frameworks in major regions are facilitating wider accessibility of these therapies through hospital networks.
Regional Outlook
The global axial spondyloarthritis drugs market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Increasing Adoption of Axial Spondyloarthritis Therapies in Europe
Rising awareness of axial spondyloarthritis and its long-term impact is contributing to the growth of the European market. Hospitals and specialized clinics are increasingly adopting advanced biologic therapies, enabling more effective disease management. Expanded access to novel treatments through supportive reimbursement policies has encouraged wider adoption among patients. Ongoing clinical research and the introduction of innovative drug formulations are strengthening the treatment landscape. Collaboration between healthcare providers and pharmaceutical companies is facilitating the dissemination of new therapies.
North America Region Dominates the Market with Major Share
Rising prevalence of axial spondyloarthritis in North America is fueling demand for advanced drug therapies. Hospitals and specialty clinics are increasingly adopting biologic treatments, including targeted therapies that improve patient outcomes. The presence of well-established healthcare infrastructure supports early diagnosis and continuous monitoring, enhancing treatment effectiveness. Expanding research initiatives and ongoing clinical trials are introducing novel therapies that strengthen market growth. Patient awareness campaigns and education programs have improved therapy adherence and facilitated wider acceptance of advanced drugs.
Market Players Outlook
The major companies operating in the global axial spondyloarthritis drugs market include AbbVie Inc., Amgen Inc., Eli Lilly and Co., Johnson & Johnson Co. (Janssen Biotech, Inc.) and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In July 2025, Lupin Limitedsigned a global license and supply agreement with Zentiva Group to commercialize its biosimilar Certolizumab Pegol. Under the agreement, Zentiva will handle sales in Europe and CIS markets, while Lupin will manage commercialization in the USA and Canada.
- In September 2024, the U.S. FDA approved BIMZELX (bimekizumab?bkzx) for multiple indications, including active non-radiographic axial spondyloarthritis, ankylosing spondylitis, and psoriatic arthritis.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global axial spondyloarthritis drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Axial Spondyloarthritis Drugs Market Sales Analysis – Type| Application| ($ Million)
- Axial Spondyloarthritis Drugs Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Axial Spondyloarthritis Drugs Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Axial Spondyloarthritis Drugs Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Axial Spondyloarthritis Drugs Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Axial Spondyloarthritis Drugs Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Axial Spondyloarthritis Drugs Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Axial Spondyloarthritis Drugs Market Revenue and Share by Manufacturers
- Axial Spondyloarthritis Drugs Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Amgen Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Co.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson Co. (Janssen Biotech, Inc.)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Axial Spondyloarthritis Drugs Market Sales Analysis by Type ($ Million)
- Certolizumab Pegol
- Etanercept Biosimilar
- Ixekizumab
- Secukinumab
- Others
- Global Axial Spondyloarthritis Drugs Market Sales Analysis by Application ($ Million)
- Clinic
- Hospital
- Homecare
- Regional Analysis
- North American Axial Spondyloarthritis Drugs Market Sales Analysis – Type| Application| Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Axial Spondyloarthritis Drugs Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Axial Spondyloarthritis Drugs Market Sales Analysis –Type| Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Axial Spondyloarthritis Drugs Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Amgen Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biocon Biologics Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biogen International GmbH and Reata Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bio-Thera Solutions, Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Celltrion, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Enzene Biosciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fresenius Kabi USA, LLC
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson Co. (Janssen Biotech, Inc.)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Organon & Co.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reliance Life Sciences Pvt Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Samsung Bioepis Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shanghai Henlius Biotech, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- UCB, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Axial Spondyloarthritis Drugs Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Axial Spondyloarthritis Certolizumab Pegol Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Axial Spondyloarthritis Etanercept Biosimilar Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Axial Spondyloarthritis Ixekizumab Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Axial Spondyloarthritis Secukinumab Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Axial Spondyloarthritis Other Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Axial Spondyloarthritis Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
8. Global Axial Spondyloarthritis Drugs For Clinic Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Axial Spondyloarthritis Drugs For Hospital Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Axial Spondyloarthritis Drugs For Homecare Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Axial Spondyloarthritis Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Axial Spondyloarthritis Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
13. North American Axial Spondyloarthritis Drugs Market Research and Analysis by Type, 2025–2035 ($ Million)
14. North American Axial Spondyloarthritis Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
15. European Axial Spondyloarthritis Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
16. European Axial Spondyloarthritis Drugs Market Research and Analysis by Type, 2025–2035 ($ Million)
17. European Axial Spondyloarthritis Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
18. Asia-Pacific Axial Spondyloarthritis Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
19. Asia-Pacific Axial Spondyloarthritis Drugs Market Research and Analysis by Type, 2025–2035 ($ Million)
20. Asia-Pacific Axial Spondyloarthritis Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
21. Rest of the World Axial Spondyloarthritis Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Rest of the World Axial Spondyloarthritis Drugs Market Research and Analysis by Type, 2025–2035 ($ Million)
23. Rest of the World Axial Spondyloarthritis Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Axial Spondyloarthritis Drugs Market Share by Type, 2025 Vs 2035 (%)
2. Global Axial Spondyloarthritis Certolizumab Pegol Drugs Market Share by Region, 2025 Vs 2035 (%)
3. Global Axial Spondyloarthritis Etanercept Biosimilar Drugs Market Share by Region, 2025 Vs 2035 (%)
4. Global Axial Spondyloarthritis Ixekizumab Drugs Market Share by Region, 2025 Vs 2035 (%)
5. Global Axial Spondyloarthritis Secukinumab Drugs Market Share by Region, 2025 Vs 2035 (%)
6. Global Axial Spondyloarthritis Other Drugs Market Share by Region, 2025 Vs 2035 (%)
7. Global Axial Spondyloarthritis Drugs Market Share by Application, 2025 Vs 2035 (%)
8. Global Axial Spondyloarthritis Drugs For Clinic Market Share by Region, 2025 Vs 2035 (%)
9. Global Axial Spondyloarthritis Drugs For Hospital Market Share by Region, 2025 Vs 2035 (%)
10. Global Axial Spondyloarthritis Drugs For Homecare Market Share by Region, 2025 Vs 2035 (%)
11. Global Axial Spondyloarthritis Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
12. US Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
13. Canada Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
14. UK Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
15. France Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
16. Germany Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
17. Italy Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
18. Spain Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
19. Russia Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
20. Rest of Europe Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
21. India Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
22. China Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
23. Japan Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
24. South Korea Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
26. ASEAN Economies Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
28. Latin America Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
29. Middle East and Africa Axial Spondyloarthritis Drugs Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
